drugset / Trial / NCT04088500
A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to assess the effectiveness of re-induction with Nivolumab combined with ipilimumab.
Timeline
- Start
- 2020-09-03
- Primary completion
- 2021-11-15
- Completion
- 2021-11-15
Outcome
Outcome not reported
Stopped (Enrollment): “Slow accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | — | — |
| Subject | Nivolumab | Monoclonal antibody | — | — |